Purpose: The goal of this study was to determine the dose contributions from image guided adaptive brachythe rapy (IGABT) to individual suspicious pelvic lymph nodes (pLNN) in cervical cancer patients. Data were collected in two cancer centers, University of Pittsburgh Cancer Institute (UPCI) and University Medical Center Utrecht (UMCU).
Purpose
The combination of external beam radiotherapy (EBRT), chemotherapy and brachytherapy (BT) is the standard treatment of locally advanced cervical cancer. Imageguid ed adaptive brachytherapy (IGABT) has been widely adopted during the last years [1, 2] and guidelines have been published for treatment planning and dose reporting [3, 4] . The main advantage is dosevolume optimization, allowing adjustments to the classical pearshaped isodose patterns according to tumor regression during treatment and residual disease at the time of BT. Literature shows that combined EBRT and BT (especially IGABT) is curative for many patients with especially high local control rates [57] . However, regional recurrences do occur in the pelvic lymph nodes (pLNN) within and adjacent to radiotherapy fields [8] . Most regional recurrences include a component of marginal failure, suggesting a deficit in target volume coverage and dose delivered to suspicious nodes [9] . From earlier publications we know that brachytherapy contri butes to the pelvic nodal dose [10, 11] , but so far there is no data reported for MRI guided IGABT.
The purpose of this study was to determine the dose contributions from image guided adaptive brachyther apy (IGABT) to individual suspicious pLNN in cervical cancer patients. Data was collected in two cancer centers, University of Pittsburgh Cancer Institute (UPCI) and Uni versity Medical Center Utrecht (UMCU).
Material and methods
We performed a combined analysis of IGABT data in two institutes; University of Pittsburgh Cancer Insti tute (UPCI, USA) and University Medical Center Utrecht (UMCU, The Netherlands).
Patients and treatment

University of Pittsburgh Cancer Institute
Twentyseven patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB to IIIB cer vical cancer and enlarged pLNN were treated between January 2007 and December 2010 with IGABT high dose rate (HDR) applications. The patients received EBRT to the pelvis or combined pelvic and paraaortic region to 45 Gy in 25 fractions. The dose to suspicious pLNN was delivered with simultaneous integrated boosts (55 Gy in 25 fractions). Brachytherapy was scheduled once a week during the fourth or fifth week of treatment, and twice a week after completion of the EBRT. Computed tomo graphy (CT)/magnetic resonance imaging (MRI) compat ible tandemring applicators (Nucletron, an Elekta com pany, Elekta AB, Stockholm, Sweden) were used with MRI-based planning for the first BT fraction followed by CTbased planning for subsequent treatments [6, 12] . The tandem length ranged from 40 to 60 mm, the ring tandem angle was 45° to 60°, and ring diameter was 26 34 mm. All patients were treated with 5 HDR fractions of 5.06.0 Gy per fraction (reference dose) depending on the stage of disease and response to treatment. Planning aim was to cover 90% of the HRCTV volume with the reference dose. Treatment planning optimization was performed us ing a combination of graphical and manual tools. For every patient, body mass index (BMI) was calculated.
University Medical Center Utrecht
Fifteen patients with FIGO stage IBI to IVA cervical cancer and enlarged pLNN were treated between May 2009 and September 2011. Treatment consisted of EBRT to the clinical target volume as described by van de Bunt et al. [13] combined with 3D imageguided intracavitary or combined intracavitary/interstitial pulsed dose rate (PDR) BT applications. The EBRT dose was 45 Gy in 25 frac tions. Brachytherapy consisted of two PDR applications of 32 pulses of 0.6 Gy (2 × 19.2 Gy planning aim) with the first insertion after 22 EBRT fractions, and the second one after completion of EBRT. Pulsed dose rate was de livered in a 24hour schedule, one pulse per hour. Dose was prescribed to 90% of the HRCTV volume. Treat ment planning optimization was performed using a com bination of graphical and manual tools. Brachytherapy was performed using the Utrecht Interstitial Applicator, a CT/MR compatible tandemovoid applicator that al lows additional interstitial needle placement (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden). For the first BT fraction, only the intracavitary part of the ap plicator was used. In six of the fifteen patients, the dose to 90% of the HRCTV (D 90 HR-CTV) of the first application did not meet the planning aim. In this group the second application was performed with 16 additional interstitial needles. The number of needles and their position and depth of insertion were based on dosimetric and spatial shortcomings of the first application. After BT, all pa tients received an additional 3Dconformal EBRT boost of 10 to 14 Gy in 5 to 7 fractions to suspicious pLNN, taking into account the dose contribution of BT. Also for these patients, BMI was calculated.
Imaging and contouring
University of Pittsburgh Cancer Institute
At UPCI, all 27 patients had MRI examination (GE SIGNA HD excite 1.5T, GE Health Care, Milwaukee, WI, USA); T2weighted sequences with 3.5 mm slice thick ness for the first BT fraction. For the following four frac tions, a CT examination was performed (GE LightSpeed Ultra64 slice per rotation, GE Health Care, Milwaukee, WI, USA) with 2.5 mm slice thickness. CT images were acquired without intravenous contrast, but with 60 ml diluted contrast injected into the bladder. HRCTV and or gans at risk (OAR) were contoured on an Eclipse TM work station for each fraction, according to the GEC ESTRO recommendations [3, 4] . Thereafter, they were transferred to the Nucletron Plato Brachytherapy Planning system (version 14.3, Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden) for threedimensional planning.
University Medical Center Utrecht
At UMCU, all fifteen patients had MRI examination for each application (Gyroscan NT Intera 1.5 T, Philips Medical Systems, Best, The Netherlands) based on the institutional protocol, which includes T2weighted turbo spinecho images with 3 or 4.5 mm slice thickness, and a balanced steadystate free precession scan with a slice thickness of 1.5 mm for applicator reconstruction purpos es [14] . HRCTV and OAR were contoured in VolumeTool [15] according to GEC ESTRO recommendations [3, 4] . Contours were transferred into the Plato Brachytherapy Planning System, and applicator reconstruction and treat ment planning was performed.
Node contouring
Gross nodal volume for each pLNN was contoured based on imaging information. Individual pLNN were contoured on the images performed for each BT fraction. Pretreatment MRI or PETCT information was used to guide identification of residual pLNN on BT scans. In case of complete response of the enlarged pLNN, the areas previously occupied by the individual nodes were con toured. Pelvic lymph nodes contours were generated by a specifically trained resident and verified by a radia tion oncologist experienced in gynecological tumors in UPCI and UMCU, respectively.
Analysis
The dose contributions (D 90 ) to each individual pLNN were calculated from dosevolume histograms (DVH) for each fraction; both as absolute physical dose and as percentage of the reference dose. The doses were expressed as biologically equivalent dose in 2 Gy frac tions (EQD2) using LQmodel (with α/β = 10 for tumor, α/β = 3 for OAR and half time of repair of 1.5 hours) [16] and were added for all fractions. Furthermore, the D 90 for the HRCTVs were determined in EQD2. In order to get an estimate of the influence of radiobiology, the PDR data were recalculated as if given by HDR in 4 fractions of 7 Gy and scaled for OAR constraints (clinically used HDR schedule in our institute).
For every patient, we determined the total reference air kerma (TRAK). Total reference air kerma divided by the reference dose was considered as an indicator of the volume encompassed by the 100% isodose.
Anatomical nodal regions
The contoured pLNN were grouped by three physi cians into anatomical nodal regions, based on Radiation Therapy Oncology Group (RTOG) definitions of pelvic nodal groups for intensitymodulated radiation thera py (IMRT) [17] and other published literature [1820] . The common iliac region (CI) covers the area around the common iliac vessels from the aortic to iliac bifurca tion. The internal iliac region (II) is defined as an area of 7 mm around and along the internal iliac vessels, exclud ing pLNN ventrally to external iliac vessels. From the point where the internal and external iliac vessels spread to a distance of more than 7 mm, the space around and along external iliac artery is called external iliac region (EI). The obturator region (OB) encompasses the space bordered by internal and external iliac regions.
Results
For patients characteristics see Table 1 . In UPCI, 27 pa tients underwent 135 tandemring based HDR ap plications in total. Fiftyseven pLNN were detected with a minimum of 1 and a maximum of 9 per patient. The mean HRCTV of these patients was 36.9 cm 3 (range 21. (Table 2 ). Figure 1 shows an illustration of the 3D EQD2 distribution of a BT PDR fraction displaying pLNN with different locations and different dose con tributions. Table 3 and Figure 2 show the dose contributions of IGABT to the different nodal regions. In UPCI, but not in UMCU we saw a tendency that dose decreases from obtu rator to external, internal and common iliac nodes. The dose contributions of IGABT to individual pLNN varied impres sively in both centers (range ~5 to > 90% of the reference dose). After having excluded the few parametrial, inguinal and perirectal nodes from the UMCU data set (leaving 35 pLNN for the comparison; see Table 2 ), the nodes re ceived on average 16.7% (range 6.834.7%) of the reference dose, corresponding to 5.6 Gy (range 2.212.0 Gy) EQD2. Furthermore, recalculating the UMCU PDR into HDR values, resulted in a reduced mean D90 of 3.9 Gy (range 1.5 8.2 Gy) EQD2, and a smaller difference with UPCI values. 
UPCI -University of Pittsburgh Cancer Institute, UMCU -University Medical Center Utrecht, HDR -high dose-rate, PDR -pulsed dose-rate, pLNN -pathologically enlarged pelvic lymph-nodes, SD -standard deviation, HR-CTV -high risk-CTV, D 90 -dose to 90% of the volume, ref. dose -reference dose, EQD2 -biologically equivalent dose in 2-Gy fractions **PDR data were recalculated as if given by HDR in 4 fractions of 7 Gy and scaled for OAR constraints
Discussion
To our knowledge, this retrospective interinstitu tional study represents the first dosimetric analysis of MRI based IGABT dosecontributions to pelvic lymph nodes in patients with advanced cervical cancer. Since the introduction of image guided BT, local control in cervical cancer has increased [5, 7] , but regional control is still a matter of concern [6, 9] . Additionally, modern imaging modalities allow a better visualization of pLNN [21] and help to consider them suspicious or not, which influences our intentions to treat nodal disease.
For accurate dose reporting and for our understand ing of nodal dose response relations it is essential to learn how EBRT and BT contribute to the treatment of indivi dual affected lymph nodes. More detailed information on the dose administered per node will also help us to fur ther optimize nodal boosting.
Isodose patterns of traditional Manchester system BT are pear shaped and symmetrical. Point B in this system was thought to give an estimate of the dose contribution I n t e r n a l i l i a c E x t e r n a l i l i a c O b t u r a t o r P a r a m e t r i a l I n g u i n a l P e r i r e c t a l to the lateral parametrium and the regional nodes. It is located at the level of point A, 5 cm lateral from the cen ter of the tandem and gets approximately 15% to 25% of the point A dose. Lee et al. [10] already showed that the point B dose is not a good surrogate for the dose to pel vic nodes. In that study, the nodal regions defined on CT scans were overlaid with the BT dose distributions showing significantly lower dose to nodal groups than to point B (on average 5 vs. 7 Gy). Additionally, it was do cumented that there is some variation in dose delivered to the different nodal groups, defined as internal iliac, external iliac, and obturator nodes.
In our study, we investigated the contribution of individualized IGABT to the pLNN. We computed the BT dose to individual nodes located in the different groups by using the images at time of BT and the opti mized BT treatment plans. We found a variety of dose levels in individual nodes and patients, but no general dose level differences when comparing the earlier defined nodal groups. This finding might be due to the fact that the spatial dose distributions of IGABT in the central pel vis can be quite asymmetric as they follow the target and OAR locations and shapes. It can therefore be expected that individualized IGABT also individually contributes to different pLNN with the highest values to nodes in the vicinity of the HRCTV and high dose regions. Based on the data presented here, we consider to calculate the IGABT dose for the individual nodes, especially when EBRT boosting is part of the treatment schedule. Dose calculation for the different nodal regions is a rougher estimate and might still be used if individual node dose calculation is not possible. We found astonishing pLNN dose level differences in and between the two cancer centers. The IGABT dose contributions to pLNN in UPCI were on average lower than the ones in UMCU. Several factors were investigated in order to explain these findings. Part of the difference was caused by the fact that in some UMCU patients, dif ferent from UPCI, pLNN were identified in the vicinity of the HRCTV, especially in parametrium and perirectally. After excluding these nodes and their corresponding high D 90 values, the dose level difference was smaller. Ano ther part of the difference is accounted for radiobiology. After having recalculated the UMCU PDR contributions to pLNN into HDR values, the difference in dose again was smaller, but still remained. This lasting difference is due to the fact that the prescribed and administered tu mor dose in UMCU is in principal higher, irrespective of the underlying radiobiology. The on average higher D 90 HRCTV values in UMCU are corresponding to higher totally administered doses and larger BT volumes irradi ated to the reference dose.
The addition of interstitial needles to the intracavitary part of the applicator in six of the UMCU patients did not influence the dose contributions to pLNN (Fig. 3) sys tematically. A possible explanation is that the needles are used differently in individual situations. Some needles are intended to increase the dose to the lateral parts of the HRCTV, others for reducing the more centrally located D 2cc values of the OAR. However, six cases with needles might not be enough to answer this question principally. Body mass index as an independent factor was investigat ed, but did not influence the average D 90 pLNN values. Small part of the difference might be caused by the fact that two observers contoured the nodes, one in UMCU and one in UPCI. However, after having agreed upon methodology in the first instance, both observers were instructed in one centre (UMCU). It was not possible to study a potential difference between the two applicator types as both were regularly adapted to the anatomy of the individual patients.
Conclusions
The IGABT dose contribution to individual pLNN de pends on patient and treatment related factors and varies considerably. The difference is caused by the positions of the individual nodes in relation to the radiation source, by differences in radiobiology and by individual treat ment planning, and spatial dose delivery to specific HRCTV and OAR locations and shapes. Based on the data presented here, calculation of the BT dose to the in dividual pLNN for nodal dose reporting and individual node boost planning should be considered. Dose calcula tions for the different nodal regions is a rougher estimate and can be used as alternative if individual node dose calculation is not possible.
